Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.

Suppr

超能文献

作者信息

Goldenberg I S

出版信息

Cancer. 1969 Jan;23(1):109-12. doi: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1.

DOI:10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1

PMID:4884063

Abstract

摘要

相似文献

Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.

Cancer. 1969 Jan;23(1):109-12. doi: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1.

Comparison of 1 -testololactone (NSC-23759) and an estrogen-progestin combination (NSC-77622) in the treatment of metastatic breast cancer.1-睾酮内酯（NSC - 23759）与雌激素 - 孕激素联合制剂（NSC - 77622）治疗转移性乳腺癌的比较。

Cancer Chemother Rep. 1970 Aug;54(4):249-53.

High-dosage delta-1-testololactone therapy of disseminated carcinoma of the breast.

Cancer. 1967 Mar;20(3):458-61. doi: 10.1002/1097-0142(1967)20:3<458::aid-cncr2820200314>3.0.co;2-u.

[Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].醋酸甲地孕酮与醋酸甲羟孕酮治疗转移性乳腺癌的多中心III期研究中期报告

Onkologie. 1987 Apr;10(2):104-6. doi: 10.1159/000216383.

[Which hormone therapy should be used in advanced breast carcinoma in males?].男性晚期乳腺癌应使用哪种激素疗法？

Dtsch Med Wochenschr. 1988 Sep 2;113(35):1358-61. doi: 10.1055/s-2008-1067820.

Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.晚期乳腺癌的二线内分泌治疗——醋酸甲羟孕酮与氨鲁米特的随机交叉研究

Acta Oncol. 1996;35 Suppl 5:75. doi: 10.3109/02841869609083975.

A dose response evaluation of delta-1-testololactone in advanced breast cancer.

Cancer. 1974 Jan;33(1):9-13. doi: 10.1002/1097-0142(197401)33:1<9::aid-cncr2820330104>3.0.co;2-#.

[Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].

Fortschr Med. 1987 Jul 30;105(22):421-4.

[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].

Onkologie. 1987 Oct;10(5):321-3. doi: 10.1159/000216433.

Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group.晚期女性乳腺癌的雄激素与抗代谢药物联合治疗。乳腺癌协作组报告。

Cancer. 1975 Aug;36(2):308-10. doi: 10.1002/1097-0142(197508)36:2<308::aid-cncr2820360203>3.0.co;2-1.

引用本文的文献

Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.糖皮质激素对非血液系统恶性肿瘤临床疗效的系统评价

BMC Cancer. 2008 Mar 28;8:84. doi: 10.1186/1471-2407-8-84.

First generation aromatase inhibitors--aminoglutethimide and testololactone.第一代芳香化酶抑制剂——氨鲁米特和睾内酯。

Breast Cancer Res Treat. 1994;30(1):57-80. doi: 10.1007/BF00682741.

Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Cancer Chemother Pharmacol. 1980;4(4):267-9. doi: 10.1007/BF00255272.

Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Cancer Chemother Pharmacol. 1985;14(2):112-5. doi: 10.1007/BF00434347.

A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

Breast Cancer Res Treat. 1991 Aug;18(3):171-7. doi: 10.1007/BF01990033.

Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.晚期乳腺癌中使用的内分泌药物的临床药代动力学

Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002.

High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Cancer Chemother Pharmacol. 1979;2(3):175-80. doi: 10.1007/BF00258291.

Treatment of intra-abdominal and abdominal wall desmoid tumors with drugs that affect the metabolism of cyclic 3',5'-adenosine monophosphate.使用影响环磷酸腺苷代谢的药物治疗腹腔内及腹壁硬纤维瘤。

Ann Surg. 1975 Mar;181(3):299-302. doi: 10.1097/00000658-197503000-00009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验